PHARMACY

Teva files suit against Sandoz, Momenta over patent infringement

BY Alaric DeArment

JERUSALEM Teva Pharmaceutical Industries has motioned to amend a complaint against two generic drug makers over their alleged infringement of Teva’s patent on a multiple sclerosis drug.

The Israeli drug maker announced Tuesday that it had sought to amend a complaint filed against Sandoz and Momenta Pharmaceuticals in the U.S. District Court for the Southern District of New York over their attempts to make a generic version of the injected drug Copaxone (glatiramer acetate). The amended complaint has been filed with the court under seal.

Teva, which makes branded drugs in addition to being the world’s largest manufacturer of generic drugs, originally filed the suit in August 2008, alleging infringement of multiple patents covering the drug.

Teva said that Copaxone is a “highly complicated” drug to develop, and given its inability to fully characterize its active ingredients, it has “serious doubts” about another drug company’s ability to make a comparable generic version.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Walgreens, Take Care Health Systems celebrate National Nurse Practitioner Week

BY Allison Cerra

CONSHOHOCKEN, Pa. One of the nation’s largest drug store chains and its retail clinic division are applauding healthcare professionals during National Nurse Practitioner Week.

National Nurse Practitioner Week, which is held from Nov. 8 to Nov. 14, is sponsored by the American Academy of Nurse Practitioners. A 2009 RAND study published in the Annals of Internal Medicine notes that such retail health facilities as Take Care Clinics offer treatment of common ailments at a substantially lower cost than physician offices, urgent care centers and emergency rooms while providing equal or better levels of care quality. Employer-based health and wellness centers typically provide a two to four dollar return on investment for employers who utilize them while improving the health and well-being of employee populations, according to Take Care Health Systems data.

“Nurse practitioners and other front-line healthcare providers are a vital part of Walgreens vision to provide greater access to high-quality, affordable health care that is convenient to communities where people work and live,” said Hal Rosenbluth, Walgreens SVP and president of Walgreens health and wellness division. “Both the advanced clinical education and holistic patient-centric focus which are synonymous with the nurse practitioner profession have served as a catalyst for care delivery innovations that have become a key component of the solution to the nation’s healthcare crisis.”

 A wide array of healthcare professionals, including nurse practitioners, physician assistants, physicians, nurses, medical assistants, pharmacists, physical therapists, fitness and health coaches, x-ray technicians and others practice at Take Care Health facilities. The company is dedicated to empowering all health care professionals in an effort to address national healthcare challenges while creating paramount patient experiences.

“Unprecedented patient engagement scores and exceptional clinical outcomes at Take Care Clinics are a testament to the skill and ability of nurse practitioners to delight, treat and advocate for patients,” said Sandra Ryan, chief nurse practitioner officer for Take Care Health Systems. “Healthcare professionals across the country are relishing the opportunity to be a part of healthcare delivery models that challenge the status quo while improving access for all.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

URL Pharma’s gout treatment now available

BY Alaric DeArment

PHILADELPHIA A new drug for treating gout flares has become available.

URL Pharma announced the availability of Colcrys (colchicine), designed to prevent and relieve pain from acute flares of gout, a form of arthritis caused by buildups of uric acid that is deposited as needle-like crystals in the joints and soft tissues.

The Food and Drug Administration originally approved Colcrys in July to treat gout flares, approving it in October to prevent them. The drug is available in the form of 0.6-mg tablets designed to be taken twice a day.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES